Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Jasper Therapeutics will host a webcast fireside chat from the H.C. Wainwright Global Investment Conference, with a replay available for 30 days.
Rhea-AI Summary
Jasper Therapeutics (JSPR) will participate in the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026 in New York, NY.
The company’s fireside chat is scheduled for Wednesday, September 16, 2026 at 8:00 AM ET. A live webcast and a 30-day archived replay will be available via the News & Events – Events section of Jasper’s Investor Relations website.
Positive
- None.
Negative
- None.
Key Figures
- Presentation Date/Time
- September 16, 2026; 8:00 AM ET
- H.C. Wainwright Global Investment Conference
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced that management will participate at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026 in New York, NY.
H.C. Wainwright 28th Annual Global Investment Conference
Presentation Date/Time: Wednesday, September 16, 2026; 8:00 AM ET
Presentation Format: Fireside Chat
A live webcast of the fireside chat will be available on the News & Events – Events page of Jasper's Investor Relations website. An archived replay will be available on Jasper's website for 30 days following the live broadcast.
About Jasper
Jasper is a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. Jasper is advancing a pipeline of medicines including KP-104, briquilimab, and KP-701. KP-104 is a potential best-in-class dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other high unmet need nephrology disorders. Briquilimab is an anti-KIT antibody which has demonstrated positive clinical results both as a conditioning agent for stem cell transplant and mast cell mediated diseases such as chronic urticarias and allergic asthma. KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders currently advancing to the clinic.
Contacts:
Alex Gray (investors)
Jasper Therapeutics
650-549-1454
agray@jaspertx.com
Argot Partners (investors and media)
kira@argotpartners.com
FAQ
How can investors access Jasper Therapeutics’ fireside chat at the H.C. Wainwright conference?
A live webcast of the fireside chat will be available on the News & Events – Events page of Jasper Therapeutics’ Investor Relations website, with an archived replay accessible on the company’s website for 30 days after the live broadcast.
When is Jasper Therapeutics’ presentation scheduled during the H.C. Wainwright conference?
The Jasper Therapeutics fireside chat is scheduled for Wednesday, September 16, 2026 at 8:00 AM Eastern Time.